…
Salona Global Medical Device Corporation, through its subsidiaries, engages in the development, production, and sale of medical devices and products in the United States. The company's medical devices are used for pain management and physical therapy treatments, including cold/hot therapy products, neuromuscular electrical stimulation devices, transcutaneous electrical nerve stimulation devices, and ultrasound treatment devices. It also offers wearable technology and products that are used to enhance physical stability. The company was formerly known as Brattle Street Investment Corp. and changed its name to Salona Global Medical Device Corporation in December 2020. Salona Global Medical Device Corporation is headquartered in Carlsbad, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 | 2018-02-28 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 | 2018-02-28 |
| Income before tax | -4.47M | -2.67M | -1.77M | -0.76M | -7.92M |
| Net income | -4.37M | -2.67M | -2.34M | -0.76M | -8.06M |
| Selling general administrative | 9.57M | 2.29M | 0.54M | 1.73M | 2.13M |
| Gross profit | 5.96M | -0.38M | -1.19M | 0.97M | -5.67M |
| Reconciled depreciation | 0.84M | 0.00M | 0.05M | 0.26M | 0.28M |
| Ebitda | -3.24M | -2.67M | -1.67M | -0.50M | -7.53M |
| Operating income | -4.45M | -2.67M | -1.73M | -0.76M | -7.80M |
| Other operating expenses | - | - | - | - | 0.08M |
| Interest expense | 0.39M | 0.00M | 0.00M | 0.00M | 0.00M |
| Tax provision | -0.10M | 0.00M | 0.00M | 0.00M | 0.14M |
| Net interest income | -0.39M | - | - | - | - |
| Income tax expense | -0.10M | - | - | - | 0.14M |
| Total revenue | 18.31M | -0.03M | 0.35M | 3.15M | 3.94M |
| Total operating expenses | 22.76M | 2.63M | 2.08M | 3.91M | 11.74M |
| Cost of revenue | 12.35M | 0.35M | 1.54M | 2.18M | 9.61M |
| Total other income expense net | 0.37M | -1.64M | -0.04M | - | -0.12M |
| Discontinued operations | - | - | -0.57M | 1.57M | 1.57M |
| Net income from continuing ops | -4.37M | -2.67M | -1.77M | -0.76M | -8.06M |
| Net income applicable to common shares | -4.37M | -2.67M | -1.92M | -0.73M | -6.61M |
| Breakdown | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 | 2018-02-28 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 | 2018-02-28 |
| Total assets | 42.68M | 13.13M | 9.33M | 11.62M | 11.37M |
| Intangible assets | 6.93M | - | - | - | - |
| Other current assets | 0.41M | 5.56M | 0.14M | 0.50M | 0.65M |
| Total liab | 29.53M | 6.49M | 0.37M | 0.41M | 0.33M |
| Total stockholder equity | 13.15M | 6.64M | 8.97M | 11.21M | 11.04M |
| Other current liab | 15.32M | 5.44M | 0.01M | 0.01M | 0.01M |
| Common stock | 38.53M | 31.07M | 31.06M | 31.06M | 31.06M |
| Capital stock | 38.53M | 31.07M | 31.06M | 31.06M | - |
| Retained earnings | -33.36M | -28.99M | -26.33M | -24.40M | -23.67M |
| Other liab | - | 5.43M | - | - | - |
| Good will | 9.83M | - | - | - | - |
| Other assets | 0.48M | - | - | - | - |
| Cash | 8.06M | 7.08M | 8.35M | 9.30M | 6.06M |
| Total current liabilities | 24.91M | 6.49M | 0.23M | 0.28M | 0.33M |
| Short long term debt | 5.67M | - | - | - | - |
| Other stockholder equity | 1.01M | 0.94M | 1.37M | 1.21M | 1.99M |
| Property plant equipment | 5.40M | - | - | 0.01M | 0.06M |
| Total current assets | 20.04M | 13.13M | 8.89M | 11.33M | 12.37M |
| Net tangible assets | -3.61M | 6.64M | 9.50M | 11.06M | 12.09M |
| Short term investments | 0.00M | 0.49M | 0.84M | - | - |
| Net receivables | 6.60M | - | 0.40M | 1.53M | 5.67M |
| Long term debt | 0.68M | - | - | - | 0.01M |
| Inventory | 4.97M | - | - | - | - |
| Accounts payable | 2.86M | 0.48M | 0.17M | 0.19M | 0.28M |
| Non current assets total | 22.65M | 0.00M | 0.00M | 0.19M | 0.45M |
| Capital lease obligations | 4.18M | - | - | - | - |
| Breakdown | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 | 2018-02-28 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 | 2018-02-28 |
| Investments | 0.50M | 0.07M | -0.90M | -0.90M | -0.90M |
| Change to liabilities | 1.52M | 0.88M | -0.04M | -0.06M | -0.83M |
| Total cashflows from investing activities | -4.62M | 0.07M | -0.90M | -0.90M | -0.09M |
| Net borrowings | -0.04M | -0.04M | -0.04M | -0.04M | -2.21M |
| Total cash from financing activities | 3.94M | 5.43M | 5.43M | 5.43M | -2.46M |
| Change to operating activities | -1.97M | 0.39M | 0.79M | 3.02M | 4.66M |
| Net income | -4.37M | -2.67M | -1.92M | -0.73M | -6.61M |
| Change in cash | -4.45M | 4.16M | -0.95M | 3.25M | 0.11M |
| Begin period cash flow | 12.51M | 8.35M | 9.30M | 6.06M | 5.95M |
| End period cash flow | 8.06M | 12.51M | 8.35M | 9.30M | 6.06M |
| Total cash from operating activities | -3.70M | -0.98M | -0.20M | 4.04M | 3.08M |
| Issuance of capital stock | 4.26M | - | - | - | - |
| Depreciation | 0.84M | 0.84M | 0.05M | 0.16M | 0.28M |
| Dividends paid | - | - | - | 0.00M | 0.25M |
| Change to inventory | 0.25M | 0.25M | 0.25M | 0.25M | - |
| Change to account receivables | -2.07M | - | - | 1.38M | -2.14M |
| Other cashflows from financing activities | -0.66M | -0.66M | -0.66M | -0.66M | 0.00M |
| Change to netincome | 0.03M | 0.42M | 0.93M | 1.67M | 5.59M |
| Capital expenditures | 0.06M | 0.06M | 0.06M | 0.06M | 0.09M |
| Change in working capital | -0.21M | 1.27M | 1.29M | 4.35M | 3.83M |
| Stock based compensation | 1.20M | 0.24M | 0.02M | 0.10M | - |
| Other non cash items | -5.65M | - | - | - | - |
| Free cash flow | -3.76M | -0.98M | -0.13M | 4.00M | 2.98M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TLT Theralase Technologies Inc. |
0.01 2.70% |
0.19 | - | - | 90.07 | 82.51 | 90.31 | -12.06 |
| CNVI Conavi Medical Corp. |
-0.01 4.55% |
0.10 | - | - | 66.65 | - | 95.30 | - |
| PINK Perimeter Medical Imaging AI Inc |
-0.02 11.11% |
0.16 | 4.13 | - | 18.78 | 11.34 | 20.22 | -2.55 |
| CHER Cheelcare Inc. |
-0.03 2.40% |
1.22 | - | - | 20.92 | 106.42 | 21.26 | - |
Salona Global Medical Device Corporation, through its subsidiaries, engages in the development, production, and sale of medical devices and products in the United States. The company's medical devices are used for pain management and physical therapy treatments, including cold/hot therapy products, neuromuscular electrical stimulation devices, transcutaneous electrical nerve stimulation devices, and ultrasound treatment devices. It also offers wearable technology and products that are used to enhance physical stability. The company was formerly known as Brattle Street Investment Corp. and changed its name to Salona Global Medical Device Corporation in December 2020. Salona Global Medical Device Corporation is headquartered in Carlsbad, California.
3330 Caminito Daniella, Del Mar, CA, United States, 92014
800 760 6826
144
| Name | Title | Year Born |
|---|---|---|
| Mr. Leslie H. Cross | Exec. Chairman & Corp. Sec. | 1951 |
| Mr. Luke T. Faulstick | CEO & Director | 1964 |
| Dr. Rick Greenwald | Co-Founder & Pres of Simbex | NA |
| Jeffrey Chu | Exec. Officer | NA |
| Mr. Dennis T. Nelson | Chief Financial Officer | 1973 |
| Mr. Scott Rogow | VP of Sales & Marketing | NA |
| Mr. Jethro Rothe-Kushel | VP of Capital Markets & Financial Communications | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.